AbbVie (NYSE: ABBV), a prominent player in the biotechnology industry with a market capitalization of $327.63 billion and annual revenue of $57.37 billion, announced Wednesday that its migraine prevention drug atogepant demonstrated superior tolerability and efficacy compared to topiramate in a Phase 3 head-to-head clinical trial.
The TEMPLE study, which evaluated 545 adults with four or more migraine days per month, met its primary endpoint with significantly fewer patients discontinuing atogepant due to adverse events (12.1%) compared to topiramate (29.6%) over the 24-week treatment period.
The trial also showed superior efficacy for atogepant, with 64.1% of patients achieving at least a 50% reduction in monthly migraine days versus 39.3% for topiramate. All six secondary endpoints demonstrated statistical significance favoring atogepant.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.